InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: None

Sunday, 08/31/2014 11:50:10 PM

Sunday, August 31, 2014 11:50:10 PM

Post# of 345659
PRODUCT DESCRIPTION :
Product : Bavituximab
CAS# : 648904-28-3

http://webcache.googleusercontent.com/search?q=cache:SSzJUq_2RkYJ:www.parchem.com/chemical-supplier-distributor/Bavituximab-018304.aspx+&cd=1&hl=en&ct=clnk&gl=us

http://www.chemicalbook.com/SupplierMultiProduct.aspx?CBSID=15748&CBNumber=CB51090946



------------------------------------------

http://www.ncebiomed.com/index/search.html

----------------------------------------

Is this common for clinical trial drugs...?

1.Inquiries will be replied within 24 hours
2.As a manufacturer, we could supply various packages as you required
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price.
4.Fast delivery, goods arrive your office within 3 to 5 days
5.Please click "Inquiry" or "Email" below to get the price

http://www.ncebiomed.com/product/productmain/6452.html



-------------------------------------

Says "Parchem" is a supplier of Bavituximab...

http://www.parchem.com/chemical-supplier-distributor/Bavituximab-018304.aspx

------------------------------------

March 5, 2014

New Rochelle, NY – Parchem - fine & specialty chemicals has spent years cultivating business in the pharmaceutical industry, specifically as the premier supplier of APIs, specialty intermediates, and excipients. Its partnership list includes some of the top global pharmaceutical companies such as Bristol Meyers Squibb, Pfizer, and Boehringer Ingelheim. Parchem’s presence in the pharmaceutical industry market is founded upon a customer-centric, value-driven business model. As an ISO 9001 and NACD Responsible Distribution certified company, Parchem understands the importance of prioritizing quality controls, regulatory compliance, and a commitment to strong partnerships.

Parchem’s new pharmaceutical division will be spearheaded by Cindy Cardona, a well-respected chemical industry expert with a background in marketing and distribution. The newly formed alliance is ideal for both entities and will foster continued success in markets that are growing exponentially. Specifically, the strategy of launching the new division was based on PR being identified as a major hub for a number of leading pharmaceutical companies.

Ephraim Rabin, CEO of Parchem – fine & specialty chemicals, said: “We are excited about the expansion of our new pharmaceutical division being led by Cindy Cardona. She is a consummate professional with a proven track record of success in chemical sales. The new Puerto Rico division is an important part of our sustainability plan that will fuel Parchem’s continued growth in the long term.”

Parchem is the leading global marketer of specialty raw materials to the cosmetic, nutrition, coatings, pharmaceutical, and specialty chemical markets. As a global leader in fine & specialty chemical supply, Parchem has built a worldwide reputation as a vital link in the supply chain. Parchem – fine & specialty chemicals, takes pride in partnering with leaders in the pharmaceutical industry to support solutions for healthcare worldwide.

http://www.socma.com/pressroom/index.cfm?subSec=3&sub=72&articleID=4521

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News